Tip: Index histories & All-time highs

Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 26.07.2023       Knaus Tabbert AG
First Berlin Equity Research GmbH DE000A2YN504

First Berlin Equity Research hat ein Research Update zu Knaus Tabbert AG (ISIN: DE000A2YN504) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 75,00 auf EUR 83,00. Zusammenfassung: Wir heben unsere Prognose für 2023 im Vorfeld des für den 10. August geplanten Q2-Bericht [ … ]
Technical analysis
To the publication
Wed, 26.07.2023       Knaus Tabbert AG
First Berlin Equity Research GmbH DE000A2YN504

First Berlin Equity Research hat ein Research Update zu Knaus Tabbert AG (ISIN: DE000A2YN504) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 75,00 auf EUR 83,00. Zusammenfassung: Wir heben unsere Prognose für 2023 im Vorfeld des für den 10. August geplanten Q2-Bericht [ … ]
Technical analysis
To the publication
Tue, 25.07.2023       Health Italia S.p.A.
GBC AG IT0005221004

“[…] we aim to strengthen our position as a leader in the healthcare industry by prioritizing patient-centeredness, fostering innovation and embracing digitization.”    This management interview features Livia Foglia, the CEO of Health Italia S.p.A. GBC will soon initiate research coverage on Health Italia, and the co [ … ]
Technical analysis
To the publication
Tue, 25.07.2023       Health Italia S.p.A.
GBC AG IT0005221004

“[…] we aim to strengthen our position as a leader in the healthcare industry by prioritizing patient-centeredness, fostering innovation and embracing digitization.”    This management interview features Livia Foglia, the CEO of Health Italia S.p.A. GBC will soon initiate research coverage on Health Italia, and the co [ … ]
Technical analysis
To the publication
Fri, 21.07.2023       ad pepper media International N.V.
First Berlin Equity Research GmbH NL0000238145

First Berlin Equity Research hat ein Research Update zu ad pepper media International N.V. (ISIN: NL0000238145) veröffentlicht. Analyst Dr. Karsten von Blumenthal bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 3,50. Zusammenfassung: ad pepper (APM) hat für das zweite Quartal Umsatz und EBITDA ausgewiesen, [ … ]
Technical analysis
To the publication
Fri, 21.07.2023       ad pepper media International N.V.
First Berlin Equity Research GmbH NL0000238145

First Berlin Equity Research hat ein Research Update zu ad pepper media International N.V. (ISIN: NL0000238145) veröffentlicht. Analyst Dr. Karsten von Blumenthal bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 3,50. Zusammenfassung: ad pepper (APM) hat für das zweite Quartal Umsatz und EBITDA ausgewiesen, [ … ]
Technical analysis
To the publication
Tue, 18.07.2023       Spexis AG
First Berlin Equity Research GmbH CH0106213793

First Berlin Equity Research has published a research update on Spexis AG (ISIN: CH0106213793). Analyst Christian Orquera reiterated his BUY rating and maintained his CHF 1.80 price target. Abstract: Spexis AG reported FY/22 results which, adjusted for non-cash goodwill impairment of CHF 3.4m, were roughly as expected. Adjusted EBIT amounted to [ … ]
Technical analysis
To the publication
Tue, 18.07.2023       Spexis AG
First Berlin Equity Research GmbH CH0106213793

First Berlin Equity Research has published a research update on Spexis AG (ISIN: CH0106213793). Analyst Christian Orquera reiterated his BUY rating and maintained his CHF 1.80 price target. Abstract: Spexis AG reported FY/22 results which, adjusted for non-cash goodwill impairment of CHF 3.4m, were roughly as expected. Adjusted EBIT amounted to [ … ]
Technical analysis
To the publication
Tue, 18.07.2023       Pharming
First Berlin Equity Research GmbH NL0010391025

First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and decreased the price target from EUR 1.80 to EUR 1.50. Abstract: Pharming's orphan drug, Joenja, for the treatment of the rare disease, activated PI3K delta syndrome (APDS), was approved in t [ … ]
Technical analysis
To the publication
Tue, 18.07.2023       Pharming
First Berlin Equity Research GmbH NL0010391025

First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and decreased the price target from EUR 1.80 to EUR 1.50. Abstract: Pharming's orphan drug, Joenja, for the treatment of the rare disease, activated PI3K delta syndrome (APDS), was approved in t [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
About the newsfeed
#1
Where does the information come from?

The information is provided as part of a content partnership by one of Europe's leading news data providers, the Munich-based EQS Group.

#2
Will editorial changes be made?
The portal site is part of the EQS-Newswire distribution network. The information is provided 'as is'. No editorial adjustments are made. The detailed views are enriched with additional information in order to offer interested investors further research options.
#3
From which news source does the information originate?
As a rule, it is the companies themselves that provide information, either through their own public relations work or via partner agencies. Due to the wide reach of the EQS distribution network and the associated multiplier effects, this service is often used to reach interested parties quickly and in a targeted manner. The EQS Group counts almost all listed companies among its customers.
#4
Are the messages provided in real time?

The data feeds are updated at regular intervals. You can obtain the latest information directly from EQS if required. Simply follow the link below.

#5
Are there plans to expand the scope of the news?

If investor-relevant topics are involved, it is possible to connect additional data providers. In Q1/2024, mwb Research was added to the information offering in the rating area.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 25.11.2024, Calendar Week 48, 330th day of the year, 36 days remaining until EoY.